The State of Gambling Treatment Technology in 2026: What Every Provider Should Know

• Gambling treatment technology is no longer experimental. Venture-backed companies, university research programs, state regulators, and the gambling industry itself are investing heavily in digital tools for problem gambling.
• Birches Health raised $20M for gambling-specific telehealth. Kindbridge has partnered with DraftKings on responsible gambling interventions. State councils are funding technology pilots. The FDA is evaluating digital therapeutics pathways.
• The GamblingLess research from Deakin University proves that Just-In-Time Adaptive Interventions work for gambling populations -- delivering the right support at the right moment based on real-time behavioral data.
• For solo practitioners, this means the standard of care is shifting. Technology-assisted treatment is moving from "nice to have" to "expected."
• For treatment centers, this means competitive differentiation. Programs that integrate technology will attract more referrals, produce better data, and access new billing pathways.
• This is not a sales pitch. It's an honest assessment of where the field stands, where it's heading, and what providers need to know to make informed decisions.

Five years ago, "gambling treatment technology" meant a website with a self-assessment quiz and maybe a telehealth link. The tools were generic, the evidence was thin, and most providers rightfully viewed the space with skepticism.

That has changed -- substantially and quickly. In 2026, gambling treatment technology is a distinct and growing sector with serious investment, rigorous research, regulatory interest, and real-world implementation. Whether you're a solo practitioner with a part-time gambling caseload or a clinical director overseeing a residential program, the technology landscape is something you need to understand -- not to make a purchase decision right now, but to make informed choices about how you practice in the years ahead.

Here's an honest overview of where things stand.

The Investment Landscape: Real Money, Real Players

The first thing to understand is that gambling treatment technology is now attracting the kind of investment that signals a maturing market, not a speculative one.

Birches Health raised $20 million in funding to build a gambling-specific telehealth and digital treatment platform. Their model combines licensed therapists, digital tools, and data-driven care coordination specifically for gambling disorder. The funding round attracted investors who see gambling treatment as an underserved market with structural growth drivers -- expanding legalization, increasing prevalence, and a severe shortage of specialized providers.

Kindbridge Behavioral Health has been building a gambling-focused telehealth platform and made a notable move by partnering with DraftKings -- one of the largest sports betting operators in the United States. The partnership channels DraftKings users who show signs of problem gambling toward Kindbridge's clinical services. Whatever your views on the gambling industry's sincerity regarding responsible gambling, the structural reality is significant: the operators are building referral pipelines to treatment, and technology-enabled providers are on the receiving end.

State gambling councils are increasingly allocating portions of their treatment budgets to technology initiatives. Massachusetts, Connecticut, Oregon, and several other states have funded pilot programs for digital gambling treatment tools, between-session monitoring platforms, and technology-assisted aftercare. These aren't small grants -- they represent a strategic decision by state regulators that technology is part of the solution to gambling harm.

The gambling industry itself is investing in responsible gambling technology through organizations like the International Center for Responsible Gaming (ICRG) and through direct corporate initiatives. While the motivations are complex (regulatory compliance, public relations, genuine harm reduction -- in varying proportions), the effect is the same: more resources flowing toward technology that identifies and supports problem gamblers.

This investment landscape matters for providers because it indicates that gambling treatment technology is not a fad. It's a permanent part of the field. The question isn't whether technology will be integrated into gambling treatment -- it's how, by whom, and on whose terms.

The Evidence Base: From Theory to Proof

Investment alone doesn't validate an approach. What validates it is evidence, and the evidence base for technology-assisted gambling treatment has strengthened considerably.

The Deakin University GamblingLess Research

Perhaps the most important body of evidence for gambling treatment technology comes from Deakin University in Australia, where researchers have developed and tested the GamblingLess suite of digital interventions.

The GamblingLess program is built on Just-In-Time Adaptive Interventions (JITAIs) -- a framework where the system delivers specific therapeutic content at the moment it's most relevant, based on real-time data about the user's state and context. For gambling, this means delivering an urge-surfing exercise when the user reports a craving, a thought-challenging prompt when cognitive distortions are detected, or a coping strategy reminder during a high-risk time window.

The research findings are significant:

• Participants showed meaningful reductions in gambling frequency and expenditure
• JITAIs were effective both as standalone interventions and as supplements to traditional therapy
• Engagement was higher when interventions were contextually triggered rather than delivered on a fixed schedule
• Effects were maintained at follow-up assessments

The JITAI approach is important because it resolves a fundamental limitation of traditional therapy: therapeutic support has historically been available only during scheduled sessions, while gambling urges and triggers occur unpredictably throughout the week. JITAIs make support available in the moment -- not as a replacement for the therapist, but as an extension of the therapeutic framework into daily life.

The Carlbring Internet-Delivered CBT Trials

Per Carlbring and colleagues at Stockholm University have conducted multiple randomized controlled trials comparing internet-delivered CBT for gambling disorder to face-to-face CBT. The consistent finding: internet-delivered, therapist-guided CBT is non-inferior to in-person delivery. Clients in both conditions showed comparable improvements in gambling behavior, gambling-related cognitions, and psychological distress, with effects maintained at follow-up.

This research doesn't prove that digital tools are better than face-to-face therapy. It proves that the therapeutic content -- not the delivery medium -- is what matters. Which means that providers who integrate digital delivery aren't compromising care. They're expanding access to it.

Broader Digital Therapeutics Evidence

Beyond gambling-specific research, the broader digital therapeutics field is establishing evidence across behavioral health conditions. The FDA has cleared digital therapeutics for substance use disorders (reSET, reSET-O) and insomnia (Somryst/Pear-004), establishing regulatory pathways that gambling-specific applications may follow.

The National Institute on Drug Abuse (NIDA) and the Substance Abuse and Mental Health Services Administration (SAMHSA) have both published guidance supporting technology-assisted treatment as an evidence-based complement to traditional care. While gambling disorder falls under different clinical categories than substance use, the therapeutic mechanisms (CBT delivery, behavioral monitoring, engagement tracking) overlap substantially.

What This Means for Solo Practitioners

If you're a solo practitioner or small-group provider who treats gambling disorder, here's the practical reality of the technology shift.

Clients will increasingly expect digital touchpoints. The generations now developing gambling problems -- millennials and Gen Z -- grew up with apps for everything. They expect to interact with their healthcare providers between appointments, track their own progress, and engage with treatment tools on their phones. A provider who offers only weekly sessions with no between-session support will feel outdated to this population. Not because technology is necessary for good therapy, but because client expectations are shaped by every other service they use.

Referral sources will favor technology-enabled providers. State gambling councils, EAPs, courts, and managed care organizations are beginning to prioritize referrals to providers who use evidence-based digital tools. Not because they're anti-clinician, but because technology-enabled providers can demonstrate engagement, track outcomes, and provide the data that referral sources need.

New billing pathways make technology financially viable. CMS's expansion of Remote Therapeutic Monitoring (RTM) to behavioral health means that the between-session monitoring enabled by digital platforms is billable. For solo practitioners, RTM revenue of $120-150 per patient per month can meaningfully improve practice sustainability without adding clinical hours.

You don't need to build anything. The technology ecosystem now includes turnkey platforms designed for gambling treatment providers. You don't need a developer, a data scientist, or an IT department. You need a platform partner that understands gambling treatment, handles the technology, and delivers data to your clinical dashboard.

What This Means for Treatment Centers

For treatment centers and larger programs, the stakes are different but equally clear.

Aftercare is the immediate opportunity. Treatment centers lose contact with gambling clients at discharge -- precisely when relapse risk is highest. Digital aftercare tools (daily check-ins, engagement monitoring, escalation alerts) extend the treatment relationship into the critical post-discharge period. This is both a clinical improvement and a competitive differentiator.

Outcomes data is becoming a requirement. Payers and funders are moving toward outcome-based models. Treatment centers that can demonstrate client outcomes using standardized measures, tracked longitudinally through digital platforms, will command higher reimbursement rates and more referrals than those relying on service utilization data alone.

Integration with existing EHR systems matters. Treatment centers evaluating technology platforms should prioritize those that integrate with their existing clinical workflows. A standalone tool that creates duplicate documentation is a burden, not an asset. The right platform feeds data into the clinical record, informs treatment planning, and supports billing documentation without requiring clinicians to work in two systems.

Staff training is a real consideration. Technology adoption in treatment settings requires clinician buy-in, and clinician buy-in requires training that demonstrates clinical value rather than just administrative convenience. Treatment centers should plan for a structured onboarding process that shows clinicians how the data improves their clinical work, not just how it satisfies administrative requirements.

The Regulatory Landscape

Several regulatory developments are shaping the gambling treatment technology space in 2026.

FDA digital therapeutics pathways. The FDA's De Novo and 510(k) pathways for digital therapeutics are being explored by multiple companies developing gambling-specific applications. An FDA-cleared digital therapeutic for gambling disorder would be a landmark event -- establishing a regulatory standard, enabling insurance coverage, and lending clinical credibility to the category. While no gambling-specific digital therapeutic has received FDA clearance as of early 2026, several are in development pipelines.

CMS RTM expansion. CMS's inclusion of non-physiological data in Remote Therapeutic Monitoring codes (98975-98981) has created a reimbursement framework for digital gambling treatment monitoring. The 2026 addition of CPT 98979, which lowers data transmission thresholds for behavioral health applications, further reduces barriers to RTM adoption in gambling treatment.

State-level technology mandates. Several states are incorporating technology requirements into their gambling treatment funding frameworks. This includes requirements for outcome data reporting, encouragement of between-session monitoring, and in some cases direct funding for technology platform licensing.

HIPAA and data privacy considerations. As digital health tools handle sensitive gambling behavior data, privacy compliance is non-negotiable. Providers evaluating platforms should verify HIPAA compliance, data encryption standards, and policies on data ownership and sharing. The gambling treatment context adds an additional sensitivity layer -- gambling behavior data, if mishandled, could have legal and financial consequences for clients.

The Ecosystem: Who's Building What

Here's a candid map of the gambling treatment technology ecosystem as it exists in 2026.

Gambling-specific telehealth platforms (Birches Health, Kindbridge): Focused on connecting clients with gambling-specialized therapists via telehealth. Primary value is access -- solving the problem of clients who can't find a local gambling specialist.

Digital therapeutics and intervention tools (GamblingLess from Deakin, various startup-stage companies): Focused on delivering structured therapeutic content through digital platforms. Primary value is between-session support and scalable intervention delivery.

Between-session monitoring and engagement platforms (Cope Compass and others): Focused on maintaining the treatment connection between sessions, tracking engagement and outcomes, and supporting clinical decision-making with real-time data. Primary value is visibility into what's happening in the client's daily life and early detection of disengagement or escalation.

Responsible gambling tools from operators (various, often partnered with clinical platforms): Focused on identifying at-risk gamblers during active gambling and routing them toward support. Primary value is upstream intervention before someone reaches clinical severity.

Research platforms (university-affiliated tools used in clinical trials): Focused on testing specific intervention hypotheses. Primary value is evidence generation that informs the clinical tools listed above.

These categories overlap, and the boundaries between them are blurring. The point isn't to pick a category -- it's to understand that the ecosystem is diverse, growing, and increasingly connected.

What to Watch For

As the field matures, providers should pay attention to several emerging trends.

Consolidation. The current market has many small players. Consolidation is likely -- through acquisition, partnership, or attrition. Providers should evaluate platform partners based on sustainability and clinical alignment, not just features.

Evidence requirements will increase. Early adopters of gambling treatment technology have been willing to try tools based on theoretical alignment and general digital health evidence. As the field matures, payers and regulators will require gambling-specific evidence for the platforms they endorse. Providers should favor platforms that are actively conducting or participating in research.

Interoperability will matter more. As treatment becomes more technology-enabled, the ability of different systems to share data will become critical. A world where the client's telehealth platform, between-session tool, aftercare monitor, and EHR can't communicate is a world of fragmented care and duplicate documentation.

AI will become a factor. Artificial intelligence applications in gambling treatment are in early stages but developing rapidly. Potential applications include predictive modeling (identifying clients at elevated relapse risk before behavioral indicators are visible), adaptive intervention delivery, and natural language processing of client communications. Providers should approach AI with informed skepticism -- interested in the potential, critical of the hype, and insistent on evidence.

The Bottom Line

Gambling treatment technology in 2026 is real, evidence-informed, and growing. It's not replacing therapists -- it's extending their reach into the hours, days, and weeks between sessions where gambling disorder actually lives. It's not a silver bullet -- it's infrastructure that makes good clinical work more visible, more continuous, and more accountable.

Providers who engage with the technology landscape now -- critically, selectively, and with clinical outcomes as the guiding criterion -- will practice in a field that supports their work rather than one that's leaving them behind.

Providers who wait will eventually adopt the same tools. They'll just do it later, with less choice, and under more pressure.

The field is professionalizing. The standard of care is rising. The providers who shape what comes next are the ones paying attention now.

---

*